October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
1 citations
,
April 2017 in “Drugs & Therapy Perspectives” Use antiandrogens and other treatments for hair loss.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
1 citations
,
September 2024 in “Frontiers in Pharmacology” Aumolertinib effectively controls lung cancer and improves quality of life.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
March 2018 in “International Pharmacy Acta” New niosomal formulation effectively delivers aminexil through rat skin.
12 citations
,
November 2014 in “Journal of Cutaneous Medicine and Surgery” Antiviral medication valganciclovir may improve skin and hair in Trichodysplasia Spinulosa patients.
October 2025 in “Journal of Molecular Structure” Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
July 2018 in “DOAJ (DOAJ: Directory of Open Access Journals)” The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.
June 2026 in “The Journal of Steroid Biochemistry and Molecular Biology” November 2023 in “Journal of Pakistan Society of Internal Medicine.” Methotrexate is effective for rheumatoid arthritis but can cause side effects.
July 2021 in “International journal of dermatology, venereology and leprosy sciences” Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
1 citations
,
January 2014 in “Hair therapy & transplantation” The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.
22 citations
,
March 2000 in “Clinics in Dermatology” Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.